

Statistics for Biology and Health

**Antonella Bacchieri
Giovanni Della Cioppa**

Fundamentals of Clinical Research

**Bridging Medicine,
Statistics and Operations**

 Springer

Contents

Foreword	VII
Acknowledgements	XI
Contents	XIII
Introduction	XIX
1. Variability of Biological Phenomena and Measurement Errors	1
1.1. Phenotypic Variability	1
1.2. Temporal Variability	2
1.3. Measurement-Related Variability	3
1.3.1. The Measurement	3
1.3.2. Measurement Errors	7
1.4. Variability of Diagnostic Tests	10
Summary	13
2. Distinctive Aspects of a Biomedical Study. Observational and Experimental Studies	14
2.1. Distinctive Features of Biomedical Studies	14
2.2. The Study Protocol	18
2.3. Observational Studies	21
2.4. Experimental Studies	23
Summary	27

3. Observational Studies	28
3.1. Basic Designs of Observational Studies	29
3.1.1. Prospective or Cohort Studies	30
3.1.2. Retrospective Studies or Control Cases	36
3.1.3. Sample Size	40
3.2. Bias and Confounding	40
3.2.1. Control of Bias in Epidemiology	44
3.2.2. Control of the Phenomenon of Confounding	49
3.3. Advantages and Disadvantages of the Different Types of Observational Studies	53
Summary	56
4. Defining the Treatment Effect	58
4.1. From the Single Measurement to the Signal	58
4.2. Identification and Quantification of the End-Points (Individual Subject Level)	64
4.2.1. Methodological Characteristics of the End-Point	64
4.2.2. Discriminating between Primary and Secondary End-Points and between Efficacy and Safety/Tolerability End-Points	66
4.3. Identification and Quantification of the Signals (Group Level)	69
4.4. Statistical Considerations	70
4.5. Practical, Regulatory, Marketing and Pharmaco-Economic Considerations	73
4.6. Selection and Characterization of the Primary End-Point and Signal: an Example	75
4.6.1. Stage One: Define the Main Therapeutic Level	75
4.6.2. Stage Two: Define the Primary End-Point (Individual Patient Level)	77
4.6.3. Stages Three and Four: Define the Group Indicator, the Signal, and the Threshold of Clinical Relevance (Treatment Group and Study Levels)	79
4.7. More Than One Question in the Same Study: the Problem of Multiple Statistical Tests	80
4.8. Validation of Measurement Scales	84
4.9. Special Types of End-Points	85
Summary	88
5. Probability, Inference and Decision Making	90
5.1. Probability	91
5.1.1. Definitions	91
5.1.2. Probability Distribution and Probability Density Function	92
5.1.3. Normal or Gaussian Distribution	99

5.2.	Basic Concepts of Inference	100
5.2.1.	Hypothesis Testing and Statistical Formulation of the Medical Question	103
5.2.2.	Statistical Estimation as the Tool for Evaluation of Clinical Relevance	105
5.3.	Statistical Inference in the Frequentist and the Bayesian Approaches.	106
5.4.	Two Digressions: Measures of Variability and Likelihood Function	110
5.4.1.	Measures of Variability.	110
5.4.2.	Likelihood Function.	114
5.5.	Frequentist (Classical) Analysis of a Clinical Trial	119
5.5.1.	Hypothesis Testing: the Frequentist Solution.	120
5.5.2.	Estimation of the Effect: the Frequentist Solution.	135
5.6.	Bayesian Analysis of a Clinical Trial	138
5.6.1.	Hypothesis Testing: the Bayesian Solution	138
5.6.2.	Estimation of the Effect: the Bayesian Solution.	144
5.7.	Some Additional Considerations on the Frequentist and Bayesian Approaches	146
5.8.	Parametric and Non-Parametric Inference.	149
5.9.	Statistical Decision Making in the Medical Field	150
5.10.	Evidence-Based Medicine.	152
	Summary	154
6.	The Choice of the Sample	157
6.1.	Which Subjects Should Form the Sample?	157
6.1.1.	Characteristics of the Patients to be Enrolled in the Study	157
6.1.2.	Mechanism of Subject Selection	163
6.2.	How Many Subjects Should Form the Sample?	164
6.2.1.	Statistical Considerations	164
6.2.2.	Medical and Practical Aspects.	169
	Summary	171
7.	The Choice of Treatments	172
7.1.	Study Treatments.	172
7.1.1.	How Many Treatments	175
7.1.2.	What Treatments.	176
7.1.3.	Blinding of the Study Treatments.	178
7.1.4.	Packaging and Logistics.	178
7.2.	Concomitant Treatments.	180
	Summary	182

8. Experimental Design: Fallacy of “Before-After” Comparisons in Uncontrolled Studies	183
8.1. Experimental Design: Introductory Concepts	183
8.2. Before-After Comparison in a Single Group of Subjects	185
8.3. Temporal Variations of the Disease	186
8.4. Temporal Variations of Staff, Equipment and Environment	188
8.5. Statistical Regression Toward the Mean	189
8.5.1. The Basic Principle	189
8.5.2. Areas of Biomedical Experiments Affected by Regression Toward the Mean	191
8.5.3. How to Minimize the Effect of Regression Toward the Mean	193
8.6. Learning Effect	195
8.7. Psychological Effect	196
8.8. The Before-After Design Without Control Group in Oncology	197
Summary	198
9. Experimental Design: the Randomized Blinded Study as an Instrument to Reduce Bias	200
9.1. Introduction	200
9.2. Randomization as Antidote Against Selection Bias	203
9.2.1. Definition and Conceptual Framework	203
9.2.2. Types of Randomization	206
9.2.3. Other Methods for Assigning Patients to Treatments	215
9.3. Blinding of Treatments as Antidote Against Assessment Bias	216
9.4. A Priori Definition of the Statistical Methods and Populations as Antidote Against the Analysis Bias	221
9.4.1. Methods of Statistical Analysis	221
9.4.2. Analysis Populations	222
9.5. Comparison Between an Observational and an Experimental Study	224
Summary	227
10. Experimental Designs	228
10.1. Introduction	228
10.2. Parallel Group Design	233
10.2.1. Characteristics	233
10.2.2. Advantages and Disadvantages	233
10.2.3. Conditions of Applicability	234
10.3. Variants of the Parallel Group Design	234
10.3.1. Completely Randomized Parallel Group Design	234
10.3.2. Stratified Parallel Group Design	235
10.3.3. Parallel Group Randomized Block Design	239
10.3.4. Balanced Incomplete Block Design	242

10.4.	Other Designs with Comparison Between Subjects:	
	Dose-Escalation and Dose-Titration	244
10.4.1.	Dose-Escalation Design	244
10.4.2.	Dose-Titration Design	246
10.5.	Complete Cross-Over Design.	247
10.5.1.	Characteristics	247
10.5.2.	Advantages and Disadvantages	252
10.5.3.	Conditions of Applicability	255
10.6.	Variants of the Cross-Over Design	256
10.6.1.	Variants Based on the Type of Randomization	256
10.6.2.	Incomplete Cross-Over Designs	257
10.7.	Other Designs with Within-Subject Comparisons:	
	Simultaneous Treatments and Single Patient Designs	261
10.7.1.	Simultaneous Treatments Design	261
10.7.2.	Cross-Over Design on a Single Patient (or "N of 1" Design)	261
10.8.	Factorial Designs	263
10.8.1.	Characteristics	263
10.8.2.	Advantages and Disadvantages	268
10.8.3.	Conditions of Applicability	270
10.9.	Split-Plot Design.	271
10.9.1.	Characteristics	271
10.9.2.	Conditions of Applicability	273
10.10.	Non-Controlled Designs in Phase II Oncology Studies	273
	Summary	275

11. Study Variants Applicable to More than One Type of Design:

Equivalence Studies, Interim Analyses, Adaptive Plans and Repeated Measurements	277
11.1. Equivalence and Non-Inferiority Studies	277
11.1.1. Characteristics	277
11.1.2. The Statistical Analysis of an Equivalence Study	280
11.1.3. Planning and Implementation Problems	281
11.1.4. Analysis and Interpretation Problems	285
11.2. Studies with Interim Analyses and Sequential Designs	287
11.2.1. Definitions and Classification	288
11.2.2. Conditions of Applicability	290
11.2.3. Choice of the End-Points	292
11.2.4. Data Management Issues	293
11.2.5. Statistical Issues and Decision Making Criteria	294
11.2.6. Conflict of Interest and Confidentiality Issues	298
11.3. Adaptive (Flexible) Designs	299
11.4. Studies with Repeated Measurements	301
Summary	302

12.The Drug Development Process and the Phases of Clinical sx

Research	304
12.1. Overview of the Preclinical Development Process.	304
12.2. The Phases of Clinical Development.	308
12.2.1. Introduction	308
12.2.2. Phase I	309
12.2.3. Phase II	311
12.2.4. Phase III	313
12.2.5. Registration Dossier.	315
12.2.6. Phase IV	319
12.2.7. Project Management	321
12.3. The Phases of Clinical Development for Oncology Compounds .	322
12.3.1. Phase I	322
12.3.2. Phase II	323
12.3.3. Phase III	323
12.4. Accelerating Clinical Development.	325
Summary	327

Appendix: Areas under the Curve of the Standard Normal Distribution. . .	329
--	-----

References	331
----------------------	-----

Analytical Index	337
----------------------------	-----